CD274 and non-small cell lung carcinoma: In fact, most of the studies exploring radiomics to predict direct response or surrogates of response to immunotherapy (i.e., biological and molecular markers used as predictors of a patient’s response such as PD-L1) have been done in NSCLC populations.